fibro screen , page-2

Miyo

Obviously a disappointment, and responsibly they are putting it on the backburner to review it, and see if there is any value moving forward. The side benefit of liver fat measurements appears to have been positive, and they look to be moving forward with it. So, not everything is a loss.

Only disappointment, is the timing of the announcement, after market closed, after almost everyone had gone home. I wonder.....

If they balance their research costs with revenue, there is no reason why this company cannot grow over time, as you suggested.